Related Experiment Video

Updated: Dec 30, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

985

One or Two Immune Checkpoint Inhibitors?

Caroline Robert1, Emilie Lanoy2, Benjamin Besse1

  • 1Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif, France; Paris-Saclay university, 63 Rue Gabriel Péri, 94270 Le Kremlin Bicêtre, France.

Cancer Cell
|January 18, 2020
PubMed

Insights

The combination of ipilimumab and nivolumab showed varied outcomes in melanoma and lung cancer. Further research is needed to optimize the use of these immune checkpoint inhibitors.

Area of Science:

  • Immunotherapy
  • Oncology
  • Clinical Trials

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
  • The combination of ipilimumab and nivolumab targets distinct immune pathways.
  • Understanding ICI efficacy across different tumor types is crucial.

Purpose of the Study:

  • To compare the efficacy of ipilimumab and nivolumab combination therapy with standard treatments.
  • To identify differences in outcomes and predictive biomarkers for melanoma and lung cancer.
  • To address remaining questions regarding the optimal application of ICIs.

Main Methods:

  • Review of clinical trials evaluating ipilimumab and nivolumab.
  • Comparative analysis of treatment outcomes.
  • Exploration of potential predictive biomarkers.

Main Results:

  • Significant differences in outcomes were observed between melanoma and lung cancer patients.
  • Variations in the effectiveness of ipilimumab and nivolumab were noted.
  • Potential predictive biomarkers for treatment response were identified.

Conclusions:

  • The efficacy of ipilimumab and nivolumab combination therapy varies by tumor type.
  • Predictive biomarkers may guide optimal ICI use.
  • Further investigation is required to refine treatment strategies for ICIs.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.1K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
508